You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

Details for Patent: 10,278,923

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,278,923 protect, and when does it expire?

Patent 10,278,923 protects RYBELSUS and is included in one NDA.

This patent has thirty-four patent family members in twenty-three countries.

Summary for Patent: 10,278,923

Title:	Oral dosing of GLP-1 compounds
Abstract:	The present invention relates to improved uses of GLP-1 peptides in oral therapy.
Inventor(s):	Nielsen; Flemming S. (Roskilde, DK), Sauerberg; Per (Farum, DK)
Assignee:	Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:	15/651,043
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 10,278,923

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-001	Sep 20, 2019		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				METHOD OF TREATING TYPE 2 DIABETES MELLITUS	⤷ Sign Up
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-002	Sep 20, 2019		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				METHOD OF TREATING TYPE 2 DIABETES MELLITUS	⤷ Sign Up
Novo	RYBELSUS	semaglutide	TABLET;ORAL	213051-003	Sep 20, 2019		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				METHOD OF TREATING TYPE 2 DIABETES MELLITUS	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 10,278,923

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	13166205	May 2, 2013

International Family Members for US Patent 10,278,923

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014261336	⤷ Sign Up
Brazil	112015026325	⤷ Sign Up
Canada	2910903	⤷ Sign Up
Cyprus	1120730	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.